Coaches track mass daily. Cyclists chase power-to-weight ratios. Fighters cut weight classes. The World Anti-Doping Agency Executive Committee confirmed September 11, 2026, that GLP-1 receptor agonists including semaglutide and tirzepatide will not join the 2027 Prohibited List Gran Fondo Daily. Semaglutide and tirzepatide stay on the Monitoring Programme. Athletes face no athletic sanction for their use during the 2027 season.

Training groups call it cutting. Anti-doping regulators record it as weight management. GLP-1 receptor agonists bind to receptors in the gut and brain to delay gastric emptying and reduce appetite. Athletes use these peptides for rapid mass reduction. The Executive Committee decision means these compounds remain subject to data collection rather than strict liability enforcement. No out-of-competition testing penalty follows detection.

The Monitoring Programme Mechanism

The Monitoring Programme is a data collection status. It is not a prohibition. Substances on the WADA Prohibited List carry strict liability, meaning any detection triggers an adverse analytical finding and a potential athletic sanction. Substances on the Monitoring Programme do not. Athletes will not be banned from using weight-loss drugs under the 2027 rules, but the substances will remain on a monitoring list BBC Sport.

WADA added semaglutide and tirzepatide to its monitoring list in 2024 Independent. The September 11 confirmation extends that evidence-gathering posture through the 2027 season. This tracking approach follows the earlier framework where wada watches glp-1s for athlete advantage without triggering enforcement actions.

Evidence Threshold and Timeline

WADA requires evidence to justify prohibition. The agency has commissioned one study and is preparing another on the performance-enhancing potential of the drugs, known as GLP-1 receptor agonists Independent. Those studies will run during the 2027 competitive calendar. WADA will revisit its position at next year's executive committee meeting Independent. Any future prohibition following that review would take effect in 2028.

This regulatory timeline sits within a broader framework governing experimental compounds. While GLP-1 receptor agonists remain under observation, other peptides face immediate enforcement. Our GLP-1 peptide explainer covers the drug class itself, while the wider WADA, USADA and NCAA peptide rules explain how restrictions differ across sporting jurisdictions.

The September 11 decision establishes the current enforcement boundary. Athletes subject to out-of-competition testing face no strict liability for semaglutide or tirzepatide use in 2027. That is not a finding that the drugs enhance performance or are risk-free; it means WADA has not met its stated threshold for prohibition. The agency continues gathering prevalence data. The next decision point arrives when the Executive Committee reviews the commissioned studies next year.